Hexarelin: What the Research Actually Shows

What It Is

A Growth Hormone Secretagogue With a Second, Unrelated Receptor

Hexarelin is a synthetic hexapeptide developed in the 1990s as one of the original growth-hormone-releasing peptides, the same family as GHRP-6 and GHRP-2, and a chemical predecessor to newer, more selective secretagogues like ipamorelin. Like the rest of that family, it stimulates growth hormone release by activating the growth hormone secretagogue receptor (GHS-R1a), the same receptor ghrelin acts on, at both the pituitary and hypothalamic level.

What sets hexarelin apart is a second, unrelated action: it also binds CD36, a scavenger receptor with no role in growth hormone release, but with a well-documented presence in heart muscle. That second binding site is the basis for a substantial body of animal and cell-culture research into hexarelin's cardioprotective effects, a completely separate line of evidence from the growth-hormone pharmacology hexarelin is actually used for clinically.

The Evidence

Human Hormone-Release Data and Animal Cardiac-Mechanism Data, Graded Separately

Growth Hormone Release: Directly Studied in Humans for Three Decades

Human Dose-Response: Growth Hormone, Cortisol, and Prolactin

Massoud AF, Hindmarsh PC, Brook CG. "Hexarelin-induced growth hormone, cortisol, and prolactin release: a dose-response study." Journal of Clinical Endocrinology & Metabolism. 1996;81(12):4338-4341. doi: 10.1210/jcem.81.12.8954038. PMID: 8954038. This trial gave healthy adult men intravenous hexarelin at doses from 0 to 1.0 microgram per kilogram and measured the hormonal response. Growth hormone release rose in a dose-dependent fashion, as expected for this peptide class, but so did cortisol and prolactin, at doses well within the range that also released growth hormone. This is the first and most direct human evidence for hexarelin's defining limitation relative to newer, more selective secretagogues: it does not release growth hormone in isolation.

Human Clinical Trial, Healthy Men · Endpoint: Dose-Dependent GH, Cortisol, and Prolactin Release, IV Administration

Repeated Subcutaneous Dosing: 24-Hour Hormone Secretion

Maccario M, Veldhuis JD, Broglio F, Di Vito L, Arvat E, Deghenghi R, Ghigo E. "Impact of two or three daily subcutaneous injections of hexarelin, a synthetic growth hormone (GH) secretagogue, on 24-h GH, prolactin, adrenocorticotropin and cortisol secretion in humans." European Journal of Endocrinology. 2002;146(3):310-318. doi: 10.1530/eje.0.1460310. PMID: 11888836. This study tested the dosing pattern closer to actual clinical use, two or three subcutaneous injections daily in healthy volunteers, and tracked GH, prolactin, ACTH, and cortisol across a full 24-hour period. Repeated dosing amplified 24-hour GH output as intended, but the same non-selectivity seen in the single-dose study persisted with each injection. This confirms the cortisol and prolactin co-release isn't a single-dose artifact; it's a consistent feature of how hexarelin engages its receptor, present across the injection schedule patients actually use.

Human Clinical Trial, Healthy Volunteers · Endpoint: 24-Hour GH/PRL/ACTH/Cortisol Secretion, Repeated SC Dosing

No Loss of Effect With Short-Term Repeated Dosing, Even in Older Adults

Ghigo E, Arvat E, Gianotti L, Grottoli S, Rizzi G, Ceda GP, Boghen MF, Deghenghi R, Camanni F. "Short-term administration of intranasal or oral hexarelin, a synthetic hexapeptide, does not desensitize the growth hormone responsiveness in human aging." European Journal of Endocrinology. 1996;135(4):407-412. doi: 10.1530/eje.0.1350407. PMID: 8921821. One legitimate question for any GH secretagogue is whether the pituitary simply stops responding with repeated use. This trial tested that in older adults, a population with reduced baseline GH-IGF-1 axis function, using short-term repeated intranasal or oral hexarelin, and found no drop-off in the GH response over the treatment period. Reassuring on short-term tachyphylaxis specifically, though it doesn't address months-long courses, and it tested intranasal and oral routes rather than the subcutaneous injection more commonly used today.

Human Clinical Trial, Older Adults · Endpoint: GH Response Over Repeated Short-Term Dosing, Intranasal/Oral Routes

The Separate Cardioprotective Mechanism: Animal and Cell Data Only

The Second Receptor: CD36, Independent of Growth Hormone

Mao Y, Tokudome T, Kishimoto I. "The cardiovascular action of hexarelin." Journal of Geriatric Cardiology. 2014;11(3):253-258. doi: 10.11909/j.issn.1671-5411.2014.03.007. PMID: 25278975. This review lays out the mechanistic case for hexarelin's second, unrelated action: binding to CD36, a scavenger receptor expressed in cardiac tissue with no connection to the growth-hormone-releasing GHS-R1a receptor. The distinction matters clinically, because whatever cardiac effects hexarelin has are not a downstream consequence of raising growth hormone; they happen through a completely separate signaling pathway. Everything below traces back to this same CD36 pathway, studied in animal and cell models, not in human hearts.

Narrative Review · Summarizes the Non-GHS-R, CD36-Mediated Cardiac Mechanism

Protecting Heart Muscle Cells From Angiotensin II-Induced Cell Death

Pang JJ, Xu RK, Xu XB, Cao JM, Ni C, Zhu WL, Asotra K, Chen MC, Chen C. "Hexarelin protects rat cardiomyocytes from angiotensin II-induced apoptosis in vitro." American Journal of Physiology-Heart and Circulatory Physiology. 2004;286(3):H1063-H1069. doi: 10.1152/ajpheart.00648.2003. PMID: 14615277. Working with cultured rat heart muscle cells, this study exposed cardiomyocytes to angiotensin II, a hormone known to trigger apoptosis during heart failure and remodeling, and found that hexarelin pretreatment substantially reduced that cell death. This is cell-culture data, not a live-animal or human study, but it's the direct mechanistic basis for hexarelin's anti-apoptotic reputation.

Rat Cardiomyocyte Cell Culture · Endpoint: Reduced Angiotensin II-Induced Apoptosis, In Vitro Only

Reduced Cardiac Fibrosis in a Live-Animal Hypertension Model

Xu X, Ding F, Pang J, Gao X, Xu RK, Hao W, Cao JM, Chen C. "Chronic administration of hexarelin attenuates cardiac fibrosis in the spontaneously hypertensive rat." American Journal of Physiology-Heart and Circulatory Physiology. 2012;303(6):H703-H711. doi: 10.1152/ajpheart.00257.2011. PMID: 22842067. The strongest animal evidence behind the antifibrotic claim: chronic hexarelin dosing in spontaneously hypertensive rats, a standard model of hypertensive heart disease, measurably reduced cardiac fibrosis, the scarring process that stiffens heart tissue and drives disease progression. Part of the effect tracked with a reduction in blood pressure itself, which the authors note as a contributing factor alongside any direct antifibrotic action. Real in vivo evidence, not just cell culture, but still rat data with no human cardiac trial behind it.

Live-Animal Model, Hypertensive Rat · Endpoint: Reduced Cardiac Fibrosis, Chronic Dosing, Rodent Only

The Mechanism Behind the Fibrosis Finding: Fibroblasts and Collagen

Xu X, Pang J, Yin H, Li M, Hao W, Chen C, Cao JM. "Hexarelin suppresses cardiac fibroblast proliferation and collagen synthesis in rat." American Journal of Physiology-Heart and Circulatory Physiology. 2007;293(5):H2952-H2958. doi: 10.1152/ajpheart.00004.2007. PMID: 17766487. This companion mechanistic study explains what's happening at the cell level behind the fibrosis finding above: hexarelin directly suppressed proliferation of cardiac fibroblasts, the cells that lay down the collagen making up fibrotic scar tissue, along with the collagen synthesis those cells were producing. Like the apoptosis study above, this is cultured-cell data, and it comes from the same small cluster of investigators (Xu, Pang, Cao, and Chen) responsible for most of the fibrosis and apoptosis literature on this compound, a concentration worth naming plainly rather than treating each paper as independent confirmation.

Rat Cardiac Fibroblast Cell Culture · Endpoint: Reduced Fibroblast Proliferation and Collagen Synthesis, In Vitro Only

Preserved Heart Function After a Heart Attack in Mice

McDonald H, Peart J, Kurniawan N, Galloway G, Royce S, Samuel CS, Chen C. "Hexarelin treatment preserves myocardial function and reduces cardiac fibrosis in a mouse model of acute myocardial infarction." Physiological Reports. 2018;6(9):e13699. doi: 10.14814/phy2.13699. PMID: 29756411. This later study moved from chronic hypertension to a direct heart-attack model, surgically inducing myocardial infarction in mice and then treating with hexarelin. Treated mice showed better-preserved heart function and less fibrosis than untreated mice. Chen C, the senior author across most of this literature, is involved here too, so this doesn't fully resolve the concentration noted above, but it does extend the finding to a more clinically relevant injury model than chronic hypertension alone.

Live-Animal Model, Mouse Myocardial Infarction · Endpoint: Preserved Cardiac Function, Reduced Fibrosis, Rodent Only

Independent Replication: A Separate Group, a Different Specific Mechanism

Huang J, Li Y, Zhang J, Liu Y, Lu Q. "The Growth Hormone Secretagogue Hexarelin Protects Rat Cardiomyocytes From in vivo Ischemia/Reperfusion Injury Through Interleukin-1 Signaling Pathway." International Heart Journal. 2017;58(2):257-263. doi: 10.1536/ihj.16-241. PMID: 28321024. This study, from a group with no overlap in authorship with the fibrosis papers above, tested hexarelin in a live rat model of ischemia-reperfusion injury, the damage that occurs when blood flow is restored after a heart attack, and found protection mediated through an interleukin-1 signaling pathway, again independent of growth hormone. Independent replication from a separate lab, using a different specific mechanism than the fibroblast/collagen work above, is a genuine point in favor of the broader CD36-mediated cardioprotection story, even though this too is rat data.

Live-Animal Model, Rat Ischemia-Reperfusion · Endpoint: Cardiomyocyte Protection via IL-1 Signaling, Independent Research Group, Rodent Only

Suppressed Atherosclerotic Plaque and Foam Cell Formation in a Diet-Induced Rat Model

Pang J, Xu Q, Xu X, Yin H, Cao JM, Wu XJ, Peng J, Chen X, Chen C. "Hexarelin suppresses high lipid diet and vitamin D3-induced atherosclerosis in the rat." Peptides. 2010;31(4):630-638. doi: 10.1016/j.peptides.2009.11.010. PMID: 19931584. This is the primary hexarelin study behind claims that the peptide reduces atherosclerotic plaque and foam cell formation. In rats fed a high-lipid diet plus vitamin D3 to induce vascular calcification and plaque, chronic hexarelin dosing suppressed atherosclerotic plaque and neointima formation, reduced vascular smooth muscle cell proliferation, reduced foam cell formation from oxidized-LDL loading, and raised serum nitric oxide. It's a real, hexarelin-specific finding, but it is a single rat study with no independent replication and no human data, so it belongs here as preclinical evidence, not as an established anti-atherosclerotic effect.

Rat Model, Diet-Induced Atherosclerosis · Endpoint: Reduced Plaque, Neointima, and Foam Cell Formation; Increased NO, Rodent Only

The Macrophage Mechanism Behind the Plaque Finding: Cholesterol Out Instead of Cholesterol In

Avallone R, Demers A, Rodrigue-Way A, Bujold K, Harb D, Anghel S, Wahli W, Marleau S, Ong H, Tremblay A. "A growth hormone-releasing peptide that binds scavenger receptor CD36 and ghrelin receptor up-regulates sterol transporters and cholesterol efflux in macrophages through a peroxisome proliferator-activated receptor gamma-dependent pathway." Molecular Endocrinology. 2006;20(12):3165-3178. doi: 10.1210/me.2006-0146. PMID: 16959872. On macrophages, CD36 normally helps take up oxidized LDL, one of the steps that turns a macrophage into a cholesterol-loaded foam cell inside a developing plaque, and PPAR-gamma activation downstream of that uptake can itself increase CD36 further, a feedback loop that reinforces lipid accumulation. In cultured human and mouse macrophages, this study found hexarelin binding both CD36 and GHS-R1a and activating PPAR-gamma, but instead of feeding that feedback loop, hexarelin left CD36 expression essentially unchanged while increasing LXR-alpha roughly threefold along with the cholesterol-export transporters ABCA1 and ABCG1, and produced a 30 percent increase in cholesterol effluxed out of the cells onto HDL. That's a plausible mechanistic bridge to the reduced plaque and foam-cell findings in the rat study above: rather than reinforcing lipid accumulation the way the typical oxidized-LDL/CD36/PPAR-gamma loop does, the signal hexarelin triggers through the same receptor appears to push macrophages toward exporting cholesterol instead. This is cell-culture evidence, not a demonstration that hexarelin reduces atherosclerosis or cardiovascular events in a living artery or in a person, and for hexarelin specifically it is one study with no independent replication. A closely related, CD36-selective analog (EP 80317) and, separately, ghrelin itself have each been shown to trigger comparable cholesterol-efflux signaling through CD36, suggesting this may be a shared property of this receptor's ligands rather than a one-off finding specific to hexarelin (Bujold et al., 2009; Demers et al., 2009).

Human/Mouse Macrophage Cell Culture · Endpoint: PPAR-Gamma Activation, Increased LXR-Alpha/ABCA1/ABCG1 and Cholesterol Efflux Without Increased CD36, In Vitro Only

Improved Liver and Fat Lipid Handling Through the Same CD36/PPAR-Gamma Pathway, in a Different Tissue

Mosa R, Huang L, Wu Y, Fung C, Mallawakankanamalage O, LeRoith D, Chen C. "Hexarelin, a growth hormone secretagogue, improves lipid metabolic aberrations in nonobese insulin-resistant male MKR mice." Endocrinology. 2017;158(10):3174-3187. doi: 10.1210/en.2017-00168. PMID: 28977588. This is a second, independent hexarelin study of the same CD36/PPAR-gamma pathway described above, but run in liver, fat, and muscle tissue in insulin-resistant mice rather than in vascular macrophages. Twelve days of hexarelin lowered plasma and liver triglycerides by roughly a quarter to a third, improved glucose and insulin tolerance, and shifted body composition toward more lean mass and less fat mass without changing total weight, alongside upregulation of PGC-1alpha, LPL, HSL, and UCP-1 in fat tissue downstream of CD36/PPAR-gamma activation. Real and hexarelin-specific, but it is evidence for a metabolic-syndrome application, not a direct demonstration that this pathway reduces foam cells or plaque in an artery wall.

Mouse Model, Insulin-Resistant (MKR) · Endpoint: Reduced Hepatic/Plasma Triglycerides, Improved Glucose Tolerance, via Hepatic/Adipose CD36-PPAR-Gamma, Rodent Only

A Complication in the Cardioprotective Framing: the Same Receptor Also Causes Coronary Vasoconstriction

Bodart V, Febbraio M, Demers A, McNicoll N, Pohankova P, Moreau A, Silverstein RL, Ong H. "CD36 mediates the cardiovascular action of growth hormone-releasing peptides in the heart." Circulation Research. 2002;90(8):844-849. doi: 10.1161/01.res.0000016164.02525.b4. PMID: 11988484. This is the study that first identified CD36 as hexarelin's cardiac binding site, and it complicates the clean "CD36 means cardioprotection" story. In isolated hearts, hexarelin binding CD36 produced a dose-dependent increase in coronary perfusion pressure, meaning coronary vasoconstriction, an effect absent in CD36-deficient hearts. The authors raise the possibility that this same receptor could contribute to coronary vasospasm in the setting of atherosclerosis, which sits closer to the opposite of the anti-atherosclerotic framing elsewhere in this literature. Both things can be true of the same receptor in different vascular beds and disease states, but a guide built on the assumption that CD36 engagement is uniformly protective is claiming more consistency than a single receptor's pharmacology can guarantee.

Ex Vivo Animal Heart Model · Endpoint: CD36-Dependent Coronary Vasoconstriction, Not Uniformly Protective

A Third Mechanism: Calming Post-Heart-Attack Inflammation Through the Vagus Nerve

McDonald H, Peart J, Kurniawan ND, Galloway G, Royce SG, Samuel CS, Chen C. "Hexarelin targets neuroinflammatory pathways to preserve cardiac morphology and function in a mouse model of myocardial ischemia-reperfusion." Biomedicine & Pharmacotherapy. 2020;127:110165. doi:10.1016/j.biopha.2020.110165. PMID: 32403043. This follow-up from the same lab behind the 2018 infarction study above identified a third hexarelin mechanism in a mouse ischemia-reperfusion model, one that runs through neither GHS-R1a nor CD36. Twenty-one days of hexarelin after induced ischemia improved left-ventricular function, reduced collagen deposition and the inflammatory markers cardiac troponin-I and TNF-alpha, and shifted the heart's autonomic balance toward parasympathetic (vagal) predominance, activating the cholinergic anti-inflammatory pathway. Chen C is the senior author here as on much of this literature, so this is a third mechanism from a familiar lab rather than fully independent confirmation, but a genuinely distinct signaling route converging on the same protective outcome strengthens the overall mechanistic case.

Live-Animal Model, Mouse Ischemia-Reperfusion · Endpoint: Preserved Cardiac Function via Cholinergic Anti-Inflammatory (Vagal) Pathway, Rodent Only

A Fourth Organ and a Fourth Mechanism, Confirmed in Living Human Kidney Cells

Guan C, Li C, Shen X, Yang C, Liu Z, Zhang N, Xu L, Zhao L, Zhou B, Man X, Luo C, Luan H, Che L, Wang Y, Xu Y. "Hexarelin alleviates apoptosis on ischemic acute kidney injury via MDM2/p53 pathway." European Journal of Medical Research. 2023;28:344. doi:10.1186/s40001-023-01318-w. PMID: 37710348. This study, from a research group with no overlap in authorship with any other hexarelin paper on this page, extends hexarelin's tissue-protective evidence to a fourth organ system, kidney, and to a fourth mechanism entirely independent of GHS-R1a, CD36, and the vagal pathway above: direct binding to MDM2, a protein that normally targets p53 for degradation, confirmed by molecular docking. In rats given hexarelin before induced kidney ischemia-reperfusion injury, treatment suppressed MDM2 and p53, reduced apoptosis-related gene expression, and improved kidney pathology and function. The same protective effect on apoptosis held in cultured human kidney tubular cells (the HK-2 line) exposed to hypoxia and reoxygenation, the first time any off-label hexarelin mechanism on this page has been demonstrated in human tissue rather than only rodent tissue. This is still laboratory cell-culture and rat data, not a human clinical outcome, but it's a meaningfully different kind of evidence than everything above it.

Rat Model Plus Human (HK-2) Kidney Cell Culture · Endpoint: Reduced Apoptosis via MDM2/p53 Pathway, Independent Research Group, First Human-Cell Confirmation

Sources

References